Trial Profile
Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2018
Price :
$35
*
At a glance
- Drugs Amniotic cell therapy-NuCel (Primary)
- Indications Intervertebral disc degeneration; Spondylosis
- Focus Therapeutic Use
- 27 Jul 2018 Status changed to discontinued due to poor enrollement.
- 14 Sep 2017 Status changed from active, no longer recruiting to completed.
- 13 Oct 2016 Status changed from recruiting to active, no longer recruiting.